Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03052205 · ClinicalTrials.gov registry record · Phase 1
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
A Phase 1 study of Melanoma and Refractory Solid Tumors, sponsored by Idera Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 12
- Study locations
NCT03052205 is a Phase 1 study of Melanoma and Refractory Solid Tumors that has completed, run by Idera Pharmaceuticals. The registered enrollment target is 54 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (92% lower). The trial reports 12 study locations across 7 states.
The verdict
NCT03052205, a Phase 1 study of Melanoma and Refractory Solid Tumors, has completed, sponsored by Idera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.
Conditions Studied
Interventions
- DRUG IMO-2125
Study Locations (12)
Other
- Rambam Medical Center - Haifa
- Hadassah Medical Center - Jerusalem
- Rabin Medical Center Beilinson Campus - Petah Tikva
- The Ella Lemelbaum Institute for Immuno-Oncology - Ramat Gan
Arizona
- Scottsdale Healthcare Hospitals DBA Honor Health - Scottsdale
- The University of Arizona Cancer Center - Tucson
Pennsylvania
- St. Luke's Hospital - Easton
- UPMC Hillman Cancer Center - Pittsburgh
California
- University of California San Francisco (UCSF) - San Francisco
New York
- Roswell Park Cancer Institute - Buffalo
Ohio
- The Cleveland Clinic Foundation - Cleveland
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-06-09 |
| Est. Completion | 2019-10-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03052205
The ClinicalTrials.gov registry entry for NCT03052205 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (92% lower). The listed sponsor is Idera Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which IMO-2125 is the first listed.
NCT03052205 reports 12 study locations spanning 7 distinct geographic areas - top geographies include Other, Arizona, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03052205 about?
NCT03052205 is a clinical study titled "A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors". This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.
What is the current status of trial NCT03052205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2017-06-09. Estimated completion is 2019-10-04.
What conditions does trial NCT03052205 study?
This clinical trial studies the following conditions: Melanoma, Refractory Solid Tumors.
What interventions are being tested in trial NCT03052205?
The interventions under investigation include: IMO-2125 (DRUG).
Who is sponsoring clinical trial NCT03052205?
This trial is sponsored by Idera Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03052205 being conducted?
This trial has 12 study locations across Arizona, California, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.